Goldman Sachs upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Buy to Conviction Buy with a price target of $131.00.Analyst Jami ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE